-
O6-Benzylguanine: MGMT Inhibitor Workflow
2026-09-11
O6-Benzylguanine converts MGMT biology into a controllable pharmacology experiment, helping researchers separate DNA repair inhibition from transcriptional regulation. This workflow pairs direct MGMT blockade with alkylating-agent sensitivity, DNA-damage readouts, and the AP-2α findings reported in recurrent glioblastoma.
-
Filipin III: Mapping Cholesterol in Fibrotic Lung Biology
2026-09-10
A translational framework for using Filipin III to connect membrane cholesterol organization with SOAT1-driven macrophage dysfunction and pulmonary fibrosis, while preserving the distinction between spatial cholesterol mapping and therapeutic proof.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-09-10
A 2025 study showed that naturally occurring angiotensin peptides can alter SARS-CoV-2 spike binding to AXL, ACE2, and neuropilin-1 in sequence-dependent ways. Its deletion and residue-modification experiments connect renin–angiotensin peptide processing with viral receptor biology while also defining important limits for interpretation beyond in vitro binding assays.
-
MPS IVA Cartilage Pathology and Lysosomal Exocytosis
2026-09-09
A 2026 Disease Models & Mechanisms study links GALNS deficiency in zebrafish cartilage to enhanced lysosomal exocytosis, reduced cathepsin activity, altered glycosaminoglycan distribution, and weakened TGFβ/BMP signaling. The work shows that similar trafficking abnormalities can produce disorder-specific biochemical outcomes, refining how lysosomal storage disorders are interpreted beyond substrate accumulation alone.
-
TSPAN18, STIM1, and Prostate Cancer Bone Metastasis
2026-09-09
Zhou et al. identify TSPAN18 as a previously unrecognized regulator of STIM1 stability in prostate cancer. By competing with TRIM32-mediated ubiquitination, TSPAN18 sustains STIM1-dependent calcium entry and promotes migration, invasion, and bone metastasis, providing a mechanistic link between protein turnover and metastatic signaling.
-
Deracoxib Workflows for Canine COX-2 Research
2026-09-08
Deracoxib combines selective COX-2 inhibition with practical readouts for canine inflammation, pain, and oncology studies. This guide translates a canine mammary-cell combination study into reproducible viability, apoptosis, and nitric oxide workflows while highlighting solvent control, model selection, and translational limits.
-
O6-Benzylguanine: MGMT Inhibitor Workflows
2026-09-08
O6-Benzylguanine provides a pharmacological route to suppress MGMT-mediated DNA repair and test whether alkylating-agent resistance is repair-dependent. This workflow combines controlled pretreatment, orthogonal DNA-damage readouts, and troubleshooting strategies for cancer chemotherapy research.
-
DR5 Agonists and PD-L1 Immune Evasion in Solid Tumors
2026-09-07
Mondal and colleagues identified an unexpected immune-evasion pathway triggered by clinical DR5 agonist antibodies: caspase-8 signaling activates ROCK1 and weakens proteasome function, stabilizing tumor-cell PD-L1. The study shows that interrupting the DR5–ROCK1–PD-L1 axis can improve effector T-cell activity and antitumor responses, offering a mechanistic rationale for combination strategies in solid tumors.
-
CIP2A, PKM2 Tetramers, and NSCLC Oxidative Phosphorylation
2026-09-07
The reference study identifies CIP2A as a metabolic regulator in non-small cell lung cancer, showing that it binds PKM2, promotes PKM2 tetramer formation through phosphorylation at S287, and redirects pyruvate metabolism toward mitochondrial oxidative phosphorylation. Its findings connect CIP2A-dependent metabolic plasticity with Bcl2 regulation and suggest that combined targeting of CIP2A and glycolysis may suppress tumor growth.
-
Lysosomal Exocytosis in MPS IVA Cartilage
2026-09-05
The reference study identifies enhanced lysosomal exocytosis as a contributor to cartilage pathology in a zebrafish model of mucopolysaccharidosis type IVA, extending the disease mechanism beyond macromolecular storage. Its comparison with sialidosis reveals that increased exocytosis can produce disease-specific changes in cathepsin activity, glycosaminoglycan distribution, and TGFβ/BMP signaling.
-
Caffeic Acid Phenethyl Ester in NF-κB Assays
2026-09-04
Caffeic Acid Phenethyl Ester (CAPE) provides a practical way to perturb NF-κB signaling in cell, tumor, and exploratory neurodegeneration workflows. Its value is greatest when pathway inhibition is paired with viability, inflammatory, angiogenic, or invasion readouts rather than interpreted from a single endpoint.
-
Oxidative Stress, Ferroptosis, and TSC Mitophagy
2026-09-04
The reference study identifies a mechanistic link between oxidative stress, cGAS-STING signaling, mitophagy, and ferroptosis in tendon stem cells. Its cell and rat experiments suggest that cGAS-driven mitochondrial quality-control changes contribute to tendon injury and may provide a more selective therapeutic direction than broadly targeting cell death.
-
Physiological and Pathological Aβ in Human Synapses
2026-09-03
This study uses live human brain slice cultures to distinguish how endogenous physiological amyloid-β and Alzheimer’s disease-associated amyloid-β affect synapses. Its central contribution is showing that both excessive and reduced physiological Aβ can disrupt synaptophysin puncta, whereas pathological Aβ produces a distinct pattern involving postsynaptic uptake and presynaptic loss without the same synaptic transcript response.
-
Metal-Free Carbon Nanozymes for ALP Detection
2026-09-03
The reference study develops a metal-free carbon-dot nanozyme assay in which alkaline phosphatase hydrolysis of pyrophosphate releases catalytic activity and produces a colorimetric turn-on signal. Its kinetic analysis identifies pyrophosphate as a noncompetitive inhibitor acting at a site distinct from the carbon-dot catalytic center, enabling sensitive ALP measurement with reduced risk of metal-associated interference.
-
DiscoveryProbe FDA-approved Drug Library for TNBC Screening
2026-09-02
Use 2,320 clinically validated compounds to build a practical TNBC resistance-screening workflow around EGFR-TKI response, oxidative phosphorylation, and cancer stem-cell phenotypes. The pre-dissolved 10 mM format supports rapid drug repositioning screening, while orthogonal viability, metabolic, and imaging assays help distinguish pathway-linked sensitizers from nonspecific cytotoxins.